Overview

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Azacitidine
Cc-486
Pembrolizumab